Free Weekly Intelligence Briefing
The China biotech intelligence your BD team is missing
CDE filing translations, deal structure analysis, corporate ownership maps, and BIOSECURE compliance tracking — sourced directly from Chinese-language databases that your team can't read.
Covering $137.7B in China-to-West deal flow · The only English-language CDE filing analysis from a native Mandarin reader
What you get each week
Every Thursday, 5-7 minute read. From primary Chinese-language sources.
China Deal Analysis
We break down the week's biggest China-to-West licensing deals: financial terms, strategic rationale, and how they compare to benchmarks.
CDE Filing Intelligence
New Chinese drug filings translated and analyzed in English. What's advancing through NMPA that US BD teams should know about.
Corporate Ownership Maps
Who actually owns the Chinese company you're evaluating? We map VIE structures, SOE connections, and subsidiary chains through Chinese corporate registries.
BIOSECURE Compliance Watch
BCC list updates, enforcement timeline tracking, and what it means for your Chinese CDMO/CRO contracts.
Actionable Takeaways
Every issue ends with concrete recommendations for your next BD meeting or compliance review.
Built for: VP Business Development · General Counsel · Healthcare VCs · BIOSECURE Compliance · Law Firm Partners
See what you'll receive each week
Preview from our latest briefing
China Biotech Weekly #1: The ~$12B Signal — Why GSK-Hengrui Rewrites the Playbook
GSK-Hengrui's multi-asset deal valued at ~$12B reveals a new template for China out-licensing. Plus: 10 months to the BCC list, what CDE accepted this month, and the WuXi supply chain exposure that 34 US biotechs disclosed to the SEC.
Read the full briefing →The China biotech opportunity in numbers
China Out-Licensing 2025
$137.7B
↑ +140% YoY
Big Pharma Deals from CN
38%
→ of $50M+ deals in H1 2025
US Biotechs with CN CDMO
79%
→ have at least one contract
US BIOSECURE Tools
0
— dedicated compliance tools
Why this briefing exists
China Biotech Weekly is written by Antony Tan, a computational biologist at Harvard with research experience at the Broad Institute and a publication at NeurIPS 2025. Fluent in English, Mandarin, and Cantonese, Antony natively reads CDE filings, navigates Tianyancha and GSXT corporate registries, and translates the intelligence that US pharma teams need but can't access directly.
A $137.7B deal market deserves better intelligence than Google Translate and secondhand analyst reports. Every deal analysis, CDE translation, and corporate ownership map comes from primary Chinese-language sources — the same databases that $500/hr consultants use, delivered weekly for free.
Independence disclosure: China Biotech Weekly has no financial relationships with any Chinese biotech company, CDMO, or government entity. All analysis is independent.
Get the intelligence before your next BD meeting.
CDE filings, deal analysis, and BIOSECURE compliance updates — delivered every Thursday. Free.